RxDoctor Payments Data

Terri Hall, APRN

Family · Staffordsville, KYNPI 1891074282

Payments from drug & device makers

$3,510in general payments, 2019–2025

Across 211 payments — averaging $16.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Abbott$537
  • Johnson & Johnson$350
  • Bayer$248
  • Pfizer$163
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$115
  • plus $961 from 29 others

What the payments were for

  • Food & beverage$3,510100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,510 in reported general payments places this provider in the 85th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$48,692
Medicare patients
229
Services billed
710

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban159$130,784
EntrestoSacubitril/Valsartan150$128,877
JardianceEmpagliflozin40$32,420
XareltoRivaroxaban30$30,242
BrilintaTicagrelor35$19,524
Ranolazine ErRanolazine38$5,470
Potassium Chloride226$3,081
Metoprolol Succinate280$2,637
Diltiazem 24hr Er (Cd)Diltiazem Hcl92$1,285
Atorvastatin Calcium202$1,162
Rosuvastatin Calcium166$1,091
Furosemide321$1,009
Nitroglycerin56$935
Lisinopril166$912
Bumetanide22$898

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$163$130,784159 claims
NovartisEntresto$1,136$128,877150 claims
Boehringer IngelheimJardiance$21$32,42040 claims
Johnson & JohnsonXarelto$350$30,24230 claims
AstraZenecaBrilinta$59$19,52435 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,374 family providers in Kentucky.

Other family in Staffordsville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →